RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.

doi:10.1038/s41598-020-76933-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.

Scientific reports - 18 Nov 2020

Kim TaeHyung, Moon Joon Ho, Ahn Jae-Sook, Ahn Seo-Yeon, Jung Sung-Hoon, Yang Deok-Hwan, Lee Je-Jung, Shin Myung-Geun, Choi Seung Hyun, Lee Ja-Yeon, Tyndel Marc S, Lee Hui Young, Kim Kyoung Ha, Cai Yu, Lee Yoo Jin, Sohn Sang Kyun, Min Yoo Hong, Cheong June-Won, Kim Hyeoung-Joon, Zhang Zhaolei, Kim Dennis Dong Hwan

Abstract excerpt

DNA sequencing-based measurable residual disease (MRD) detection has shown to be clinically relevant in AML. However, the same methodology cannot be applied to fusion gene-driven subtypes of AML such as core-binding factor AML (CBF-AML). Here in this study, we evaluated the effectiveness of using DNA and RNA sequencing in MRD detection and in tracking clonal dynamics in CBF-AML. Using RNA-seq, we were able to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Core Binding Factor Alpha 2 Subunit

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factors

Share to Gene Expression Regulation, Leukemic

Share to Myosin Heavy Chains

Share to Neoplasm, Residual

Share to Oncogene Proteins, Fusion

Share to Proof of Concept Study

Share to RUNX1 Translocation Partner 1 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 33208771
DOI: 10.1038/s41598-020-76933-2
PMCID: PMC7674449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.PMID 33208771Read ↗

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.Semantic proximity Read ↗

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.Semantic proximity Read ↗

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemiaSemantic proximity Read ↗

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity Read ↗

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Personalized Circulating Tumor DNA (ctDNA) Profiling Enables Superior and Universal Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML)Semantic proximity Read ↗

Genomic DNA-based measurable residual disease monitoring in pediatric acute myeloid leukemia: unselected consecutive cohort studySemantic proximity Read ↗

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemiaSemantic proximity Read ↗

Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemiaSemantic proximity Read ↗

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.Semantic proximity Read ↗

Molecular measurable residual disease testing of blood during AML cytotoxic therapy for early prediction of clinical responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.